Figure 2.
IFN-γ–associated chemokines after treatment with emapalumab. The levels of CXCL9 (A) and CXCL10 (B), 2 chemokines induced by IFN-γ, after initiation of therapy with emapalumab. Baseline and final levels for each biomarker are indicated.
IFN-γ–associated chemokines after treatment with emapalumab. The levels of CXCL9 (A) and CXCL10 (B), 2 chemokines induced by IFN-γ, after initiation of therapy with emapalumab. Baseline and final levels for each biomarker are indicated.